Besides their well-characterized proinflammatory and proatherogenic effects, oxidized phospholipids, such as oxPAPC (oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-phosphocholine) have been shown to have beneficial responses in vascular cells via induction of antioxidant enzymes such as heme oxygenase-1. We therefore hypothesized that oxPAPC could evoke a general cytoprotective response via activation of antioxidative transcription factor Nrf2.
sequence in their 5Ј flanking sequences. 11 The ARE sequence is a regulatory element found in the promoters of a number of antioxidant and phase II detoxification enzymes, and it binds the transcription factor Nrf2, which has recently been reported to mediate the induction of OKL38 gene by oxPAPC. 12 The mechanism of Nrf2-dependent signaling bears similarities with other environmental defense systems, ie, nuclear factor B-mediated inflammatory and hypoxia inducible factor-mediated hypoxic responses. 13 Under basal conditions, Nrf2-dependent transcription is repressed by its negative regulator Keap1, which functions as an adaptor for Cul3based E3 ligase to facilitate proteasomal degradation of Nrf2. When cells are exposed to oxidative stress or electrophiles, Nrf2 accumulates in the nucleus and drives the expression of its target genes. Although it is evident that Keap1 is a critical negative regulator of Nrf2 signaling and a direct target for Nrf2-activating electrophiles, 14 -16 there are a number of complementary signaling pathways, such as those mediated by protein kinases, 17 contributing to the activation.
Based on previous findings, we hypothesized that oxPLs can trigger a stress response via Nrf2 in endothelial cells. The aim of our study was therefore to assess the role of Nrf2 in mediating the induction of GCLM, HO-1, and NAD(P)H quinone oxidoreductase-1, another Nrf2-dependent gene important for endothelial antioxidant protection. 18, 19 Moreover, the molecular characteristics of Nrf2-activating oxPLs was examined. Finally, using topical application of oxPAPC to the carotid arteries of either wild-type (WT) or Nrf2 Ϫ/Ϫ animals, we studied the role of Nrf2 in mediating the induction of antioxidant genes in vivo.
Materials and Methods
Details on phospholipids and other reagents, cell culture, cloning of the plasmids, transfection of cells with plasmids or small interfering (si)RNA, real-time quantitative PCR analysis, Western blotting and densitometric quantification, chromatin immunoprecipitation (ChIP), luciferase reporter assay, surgical application of oxPAPC to mouse carotid arteries, immunohistochemistry, and statistical analyses are provided in the expanded Materials and Methods section in the online data supplement, available at http://circres.ahajournals. org. All animal procedures were approved by the Experimental Animal Committee of the University of Kuopio.
Results

OxPAPC Activates Nrf2 and Induces HO-1, GCLM, and NQO1
On activation, Nrf2 protein accumulates in the nucleus, which subsequently drives the expression of Nrf2 target genes. We therefore first examined the effect of oxPAPC on nuclear and cytoplasmic content of Nrf2 protein, as well as the expression of HO-1, GCLM, and NQO1, well-characterized Nrf2 target genes. OxPAPC at the concentration of 50 g/mL increased Nrf2 protein assessed by Western blots in nuclear fractions ( Figure 1A ). Treatment of human umbilical vein cells (HUVECs) with 0 to 75 g/mL oxPAPC increased HO-1, GCLM, and NQO1 mRNA and protein concentration dependently ( Figure 1B) . The fold induction of HO-1 mRNA was notably higher than the other genes, largely because of very low basal expression. The induction of HO-1 by oxPAPC was rapid and preceded the induction of both GCLM and NQO1 ( Figure 1C ).
Knockdown of Nrf2 Expression by siRNA Inhibits the Induction of HO-1, GCLM, and NQO1 by OxPAPC
To assess as to whether the induction of HO-1, GCLM, and NQO1 is Nrf2-dependent, a specific siRNA against Nrf2 was used. Transfection with Nrf2 siRNA caused a significant inhibition of both Nrf2 mRNA and protein expression in comparison with nonspecific control siRNA (Figure 2A and 2B). Densitometric assessment of nuclear Nrf2 protein content relative to LaminB1 revealed Ϸ90% reduction of Nrf2 protein in cells transfected with Nrf2-siRNA and treated with oxPAPC for 4 hours, in comparison with control siRNAtransfected, oxPAPC-treated cells ( Figure 2B ). Both basal and the oxPAPC-inducible mRNA expression of GCLM and NQO1 was markedly downregulated by Nrf2 siRNA. However, although the expression of HO-1 mRNA was significantly inhibited by Nrf2 siRNA, the reduction was only Ϸ30%, suggesting that other, redundant pathways in large part mediate the induction by oxPAPC. This notion was further supported by the densitometric analysis of the Western blot data, which shows that oxPAPC-induced expression of GCLM and NQO1 protein expression normalized to ␤-actin was significantly attenuated by Nrf2-siRNA, whereas HO-1 expression showed a trend toward lower expression, yet did not reach statistical significance ( Figure 2C ).
OxPAPC Increases the ARE-Driven Gene Expression and Induces Binding of Nrf2 to the ARE Elements of NQO1 and HO-1 Promoter Regions
Nrf2 exerts its effects through binding to the ARE element of the target gene promoter regions. To study whether oxPAPC activates ARE-driven transcription, the luciferase reporter vector containing the ARE element from the human NQO1 promoter was used. A concentration of 50 g/mL oxPAPC increased ARE-driven transcription assessed by increased luciferase activity, whereas in the construct in which the consensus ARE element was mutated, both basal and inducible activity was attenuated ( Figure 3A ). On exposure to oxPAPC, there was minor residual activation of the empty pGL3-basic vector and the vector having the NQO1 core ARE mutated. The vector backbone of pGL3-luciferase expression vector has several putative consensus binding sites for transcription factors, which may be responsive to ox-PAPC. For example, it contains a concensus activator protein-1 site, which may impact the activity of the construct, because activator protein-1 has been shown to be activated by oxPAPC. 20 However, the residual activity was very low and the direct binding of Nrf2 to the NQO1 promoter on exposure to oxPAPC was verified by ChIP assay ( Figure 3B ). Treatment of HUVECs with oxPAPC also increased the binding of Nrf2 to the distal enhancer region of HO-1 gene containing multiple AREs ( Figure 3B ). These results demonstrate that oxPAPC activates ARE and increases the binding of Nrf2 to both NQO1 and HO-1 ARE elements. OxPAPC induces nuclear accumulation of Nrf2 and the expression of HO-1, GCLM, and NQO1 in a concentration and timedependent manner. A, Nuclear and cytoplasmic Nrf2 protein detected by Western blotting in HUVECs after treatment with 50 g/mL oxPAPC. Lamin B1 was used for control of nuclear proteins. B, HUVECs were treated with 0 to 75 g/mL oxPAPC for 8 hours for RNA analyses by quantitative real-time PCR (bar graphs) or 16 hours for protein (Western blots). 1,2-Dimyristoyl-sn-3-glycerophosphocholine (DMPC) (100 g/mL) was used as a nonoxidized phospholipid control. C, HUVECs were treated with 50 g/mL oxPAPC for 0 to 24 hours, and the mRNA and protein expressions were studied as above. The mRNA expression in B and C is normalized to ribosomal RNA (rRNA) and depicted as fold change vs untreated controlϮSEM (nϭ3). *PϽ0.05 in comparison with untreated controls. The Western blots are representative of 3 independent experiments.
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Characterization of the Lipid Species Inducing Antioxidant Enzymes
As shown in Figure 2 , the induction of GCLM and NQO1 by oxPAPC was critically dependent on Nrf2, indicating that the expression of these genes could be used as a readout for the Nrf2-activating effects of different classes of oxPLs. To study the effect of polar head groups in sn-3 position on Nrf2 activation, cells were stimulated by oxPLs containing identical sn-1 and sn-2 residues (palmitoyl and arachidonoyl, respectively) but different polar head groups (for a structure of PAPC, see Figure I in the online data supplement). Replacement of oxPAPC with oxidized phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, or phosphatidylserine yielded similar upregulation of GCLM and NQO1 mRNA ( Figure 4A ), suggesting that the polar head group in sn-3 residue does not play an important role in activity. Next, the significance of the sn-2 residue was examined. We found that the presence of oxidized sn-2 residue was an absolute prerequisite for activation of GCLM and NQO1 genes because neither unoxidized phospholipids nor 1-palmitoyl-2- hydroxy-sn-3-glycero-phosphocholine (lysoPC), in which only a hydroxyl group in sn-2 position is present, were active ( Figure 4A and 4B). Oxidation of PAPC yields phospholipids containing oxidatively fragmented sn-2 residues such as 1-palmitoyl-2-(5oxovaleroyl)-sn-3-glycero-phosphocholine (POVPC) and 1-palmitoyl-2-glutaroyl-sn-3-glycero-phosphocholine (PGPC) (supplemental Figure I) . 2 We next examined the effect of these on the mRNA expression of GCLM and NQO1. Exposure of HUVECs to POVPC or PGPC did not increase the expression of either gene, indicating that these are not the species responsible for Nrf2 activation ( Figure  4C ). Because POVPC contains -terminal aldehyde group, these results also show that the presence of an electrophilic group alone is not sufficient for the activity. OxPAPCcontaining esterified epoxy isoprostanes (1-palmitoyl-2-5,6epoxy isoprostane E2-sn-3-glycero-phosphocholine [PEIPC or isoprostane-PC]) (supplemental Figure I) were previously characterized as biologically active molecules. 21, 22 We found that HPLC fraction enriched in isoprostane-PC strongly upregulated GCLM and NQO1 genes ( Figure 4D ). To test whether the isoprostane ring structure is an absolute determinant of the activity, we tested the effect of oxidized palmitoyl-linoleoyl-phosphatidylcholine (oxPLPC). Linoleic acid in the sn-2 position contains only 2 double bonds and therefore cannot form prostanoids. 23 Nevertheless, oxPLPC stimulated the expression of GCLM and NQO1 genes almost as efficiently as oxPAPC ( Figure 4E ). In addition, GCLM was upregulated by PAPC-hydroperoxide (PAPC-OOH) ( Figure 4F ). The effect was blunted by the reduction of hydroperoxide to hydroxide (PAPC-OH) by triphenylphosphine ( Figure 4F and supplemental Figure II) . In summary, we found relaxed specificity with respect to the polar head groups, demonstrated critical importance of oxidized sn-2 residue, and characterized hydroperoxide-and isoprostanecontaining oxPLs as molecular species capable of inducing GCLM and NQO1 genes.
To test the role of electrophilic groups present in oxPAPC, these were reduced by sodium borohydride (NaBH 4 ). 22 Treatment with NaBH 4 reduces aldehyde, keto, epoxy, and peroxyl groups into respective hydroxyl groups. 22 The positive ion electrospray ionization/mass spectrometry analysis of ox-PAPC before and after NaBH 4 showed that signals at m/z 594.5 and m/z 828.6, (corresponding to POVPC and isoprostane-PC, respectively) were diminished and new signals at m/z 596.4 and m/z 832.6 were detected, indicating the reduction of one functional group in POVPC and 2 in isoprostane-PC (supplemental Figure III) . 2, 22 Treatment of oxPAPC with NaBH 4 partially suppressed its ability to induce GCLM and NQO1 in HUVECs ( Figure 5A ). Moreover, coincubation with nucleophilic thiol antioxidants N-acetylcysteine (NAC) and glutathione reduced the induction of these genes as well as HO-1 ( Figure 5B and supplemental Figure IV ). We also examined the effect of NAC on the induction of Nrf2 target genes by PAPCOOH and isoprostane-PC. Incubation with NAC inhibited the induction of HO-1, GCLM, and NQO1 by both species (Figure 5C and 5D). Moreover, treatment with NaBH 4 almost completely abolished the effect of isoprostane-PC on the expression of these genes ( Figure 5D ). To conclude, these data indicate that the electrophilic character of oxPAPC and its active components are largely mediating the effect on Nrf2-responsive genes, but additional mechanisms may be required for maximal induction of these genes by oxPLs.
OxPAPC Induces HO-1, GCLM, and NQO1 Through an Nrf2-Dependent Mechanism in Murine Arteries In Vivo
Finally, we wanted to examine the role of Nrf2 in mediating the expression of HO-1, GCLM, and NQO1 in vivo. To this end, oxPAPC in pluronic gel was applied to the adventitial side of surgically exposed carotid arteries of either WT C57BL/6 controls or Nrf2-KO mice as in. 24 The concentration used corresponds to concentrations of isoprostane-PC and other bioactive phospholipids that are lower than those found in the aortas of rabbits fed the atherogenic diet. 24, 25 Mouse carotid arteries consist of only 4 to 5 cell layers, allowing penetration of oxPAPC through the vessel wall. We first studied the mRNA expression of HO-1, GCLM, and NQO1 in mouse carotid arteries using quantitative real-time PCR. After 6 hours of treatment with oxPAPC, all 3 genes were significantly upregulated in WT mouse carotid arteries in comparison with controls treated with pluronic gel only ( Figure 6A ). The induction was completely abolished in the arteries of Nrf2-KO animals ( Figure 6A ). In addition, the basal expression of NQO1 was also significantly lower in Nrf2-KO mice compared with WT controls.
We next examined the HO-1 and NQO1 protein expression in mouse carotid arteries in WT and Nrf2-KO mice using immunohistochemistry. Immunohistochemical analysis of mouse carotid arteries exposed to oxPAPC for 24 hours showed increased HO-1 expression in oxPAPC-treated arteries in WT but not in Nrf2-KO arteries ( Figure 6B ). HO-1positive cells were localized mainly in the adventitia of the vessels ( Figure 6B ). The expression NQO1 protein was more uniformly increased throughout the vessel wall in oxPAPCtreated WT carotid arteries, with increased positive staining in the adventitial and medial layers and especially in the endothelial layer ( Figure 6C ). In the Nrf2-KO mouse arteries, exposure to oxPAPC did not increase NQO1 positive staining ( Figure 6C ).
Discussion
There are a number of reports showing in vitro that Nrf2 could have antiinflammatory effects in vascular cells. In cultured endothelial cells, Nrf2 is activated by shear stress, a potent antiinflammatory force. 18, 19 Overexpression of Nrf2 downregulates the tumor necrosis factor-␣-induced transcriptional increase in vascular cell adhesion molecule-1 expression and inhibits monocyte adhesion to the endothelium. 18, 26 Furthermore, Nrf2 has been shown to mediate adaptive augmentation of antioxidant defenses of vascular cells on exposure to a variety of lipid oxidation products such as oxidized LDL, a lipid-derived aldehyde 4-hydroxynonenal, or cyclopentenone prostaglandins and isoprostanes. 9, 15, 27, 28 Herein, we expand these previous studies to show that also oxPAPC can evoke a concerted Nrf2-mediated response. Moreover, we show in vivo using WT and Nrf2-null mice that oxPAPC upregulates the expression of HO-1, GCLM, and NQO1 mRNA and HO-1 and NQO1 protein in mouse carotid arteries in WT but not in Nrf2-KO mice, demonstrating the role of Nrf2 in regulating these genes also in intact vessels. Inasmuch as we have recently shown in rabbit balloon injury model that adenoviral Nrf2 gene transfer can attenuate injury-induced vascular inflammation, as well as inhibit the accumulation of oxidized LDL in the vessel wall, 29 it is conceivable that the Nrf2 response provides a mechanism by which the deleterious effects of oxPAPC are limited.
In the present study, the induction of HO-1 in vivo in mouse carotid vessels appeared to be critically dependent on Nrf2, whereas in human endothelial cells, suppression of Nrf2 expression by siRNA had a markedly smaller impact on HO-1 expression than on the other target genes GCLM and NQO1. Although both genes have been shown to contain the 2 enhancer regions in their promoters with multiple ARE binding sites, this does not unequivocally mean that the regulation of mouse and human genes is identical. Although our ChIP results clearly indicate that Nrf2 binding is increased in distal enhancer region in the HO-1 gene on oxPAPC exposure, it is evident that other, redundant pathways are involved in HO-1 induction. For example, in previous studies, cAMP-responsive element-binding protein, 6 was shown to be involved in the induction of HO-1 by oxPAPC in human endothelial cells. Also a number of other transcriptional regulators and signaling pathways, such as nuclear factor B and PPRE (peroxisome proliferator-activated receptor response element), contribute to the regulation of HO-1, 7,8 highlighting the complexity of HO-1 regulation in different cell types and by different stimuli. It is also noteworthy that in our study, the induction of HO-1 in vivo is markedly lower than the up to 100-fold induction achieved in vitro, making it likely that in the latter case redundant pathways contributing to the activation are needed for a sufficient response.
At present, the cellular receptor mediating the effect of oxPAPC on Nrf2 activation remains unclear. It also remains an open question whether the Nrf2 activating capacity of oxPLs can be modified by phospholipases, eg, by phospholipase A 2 catalyzing the cleavage at the sn-2 position, shown to reduce the proinflammatory activity of oxPAPC. 25 It is possible that intact electrophilic oxPLs could directly bind to intracellular Keap1, because phospholipids can be taken up by the cell by transbilayer movement, 30, 31 or by receptor-mediated mechanisms. 32 Keap1 has highly reactive cysteine residues, which can be modified by direct alkylation by electrophiles, including 15-deoxy-⌬ 12,14 -prostaglandin J 2 . 15, 19 Interestingly, ox-PAPC is known to contain esterified cyclopentenone isoprostanes. 22 Also, it has recently been demonstrated that oxidized phospholipids can have intracellular targets 33 and that they can covalently bind to intracellular signaling proteins, such as H-Ras. 34 However, oxPAPC may also have targets at the cell surface which could evoke the Nrf2 response. Several cell surface receptors have been proposed to be receptors for oxPLs, including PAF-receptor, 35 lysophospholipid receptors such as G2A, 36 Toll-like receptor 4, 37 and prostaglandin E2 receptor subtype 2. 38 However, the structure-function relationship found in our experiments does not support the involvement of any of these in Nrf2 activation.
It has been proposed that exposure to oxPAPC leads to activation of NAD(P)H oxidase and production of reactive oxygen species in endothelial cells, mediating downstream effects on gene expression. 12, 39 Regarding the role of NAD(P)H oxidase in Nrf2 activation, there are a few reports showing a connection. 40 -42 Unfortunately, these reports use diphenyleneiodonium to inhibit NAD(P)H oxidase. This compound is not a specific NAD(P)H oxidase inhibitor but inhibits flavoenzymes in general, some of which (eg, NQO1, glutathione reductase) are antioxidant enzymes and Nrf2 target genes. Therefore the effects of diphenyleneiodonium are difficult to interpret. We have done experiments in which we look at the effect of NAD(P)H inhibitor apocynin, as well as siRNA specific to Nox4, the major component of endothelial NADPH oxidase, 43 which has also been reported to be responsive to oxPAPC. 39 Neither apocynin nor Nox4 siRNA had any impact on Nrf2 target gene expression (results not shown). These results support the notion that secondary ROS Figure 5 . The activation of Nrf2 by oxPAPC is dependent on its electrophilic character. A, HUVECs were exposed to NaBH 4 -or mock-treated oxPAPC (113 mol/L) for 6 hours, after which the relative expression of GCLM and NQO1 was measured. The mRNA data in A and D assessed by quantitative real-time PCR were normalized to ␤ 2microglobulin and expressed as mean fold change vs controlϮSEM (nϭ3 to 4). *PϽ0.05. B and C, Cells were exposed to either 50 g/mL oxPAPC or 50 g/mL PAPCOOH for 16 hours in the presence and absence of NAC, and the protein expression of HO-1, GCLM, and NQO1 was measured by Western blot, using ␤-actin as a loading control. The blots are representative of 3 independent experiments. D, Cells were exposed to 40 mol/L isoprostane-PC in the absence or presence of NAC or to NaBH 4 -treated isoprostane-PC for 6 hours, after which the mRNA expression was assessed as in A. *PϽ0.05 isoprostane-PC vs NaBH 4 -treated isoprostane-PC; #PϽ0.05 isoprostane-PC vs isoprostane-PCϩNAC.
production by NAD(P)H oxidase is not necessary for Nrf2 activation.
In summary, our study has identified molecular mechanisms by which oxPLs induce antioxidant genes and shows the critical dependence on Nrf2 in the induction of HO-1, GCLM, and NQO1 expression by oxPAPC in vivo. We postulate that the activation of Nrf2 by oxPLs provides a mechanism by which their proatherogenic effects are limited in the vessel wall.
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Figure 6.
OxPAPC activates Nrf2 target genes in vivo in mouse carotid arteries. A, Carotid arteries of WT and Nrf2-deficient (Nrf2-KO) mice were surgically exposed and covered with 30% pluronic gel with or without 50 g oxPAPC. Animals were euthanized after 6 hours of treatment, and expression levels of HO-1, GCLM, and NQO1 were measured with quantitative real-time PCR. The mRNA expression is normalized to rRNA and depicted as mean expression relative to WT controlϮSEM. The number of animals in each group was as follows: WT control, nϭ11; WTϩoxPAPC, nϭ10; Nrf2-KO control, nϭ5; Nrf2-KOϩoxPAPC, nϭ6. *PϽ0.05 vs WT control; #PϽ0.05 vs WT treated with oxPAPC. B and C, Carotid arteries were exposed to oxPAPC for 24 hours, and the protein expression of HO-1 (B) and NQO1 (C) was studied. Arrowhead indicates HO-1 positivity. Original magnification, ϫ400. Scale barsϭ50 m. L indicates lumen; M, media, A, adventitia.
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